Our results show that CD4 testing, followed by appropriate OI screening prophylaxis, and treatment can potentially avert between 31% and 38% of deaths from TB and CM among PLHIV with AHD across a range of epidemiologic contexts in SSA. This evidence concerns the gene CD4 and tuberculosis.